An experimental drug that claims to reduce bad cholesterol is getting a lot of attention, but an Indiana cardiologist says don’t look for it to hit pharmacy shelves any time soon. Dr. Douglas Zipes with the IU School of Medicine says the injection is actually an antibody that reduces bad cholesterol by affecting a certain function in the liver.
“I think that they’ve gotten the first stage done beautifully and that’s the initial hurdle, but it clearly needs a follow up of what we call outcomes research. Does it make a difference in the clinical state of the patient,” he says.
Dr. Zipes says while it has shown to affect cholesterol levels, it has not been tested to have any other effects like existing cholesterol drugs. He says current drugs have added benefits such as the prevention or reduction of inflammation.
Dr. Zipes says while the initial studies into the injections have shown promise, additional tests need to be done to see if there is any effect on outcome or other proof that the patient has benefits greater than or equal to current available medications that address cholesterol levels.